Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Cerluten Brain Bioregulator Protocol - Peptide Dosages

Cerluten (Brain Bioregulator) Dosage Protocol A natural peptide complex extracted from animal brain/CNS tissue, sold as an oral "Cytomax" bioregulator. The real neuroprotection data belong to the registered cerebral-cortex preparation Cortexin and the syntheti

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Cerluten (Brain Bioregulator) Dosage Protocol

A natural peptide complex extracted from animal brain/CNS tissue, sold as an oral "Cytomax" bioregulator. The real neuroprotection data belong to the registered cerebral-cortex preparation Cortexin and the synthetic analog Cortagen — not to this specific extract, whose composition is proprietary. Russian-registered as a parapharmaceutical; not a drug and not FDA-approved.

A natural peptide complex extracted from animal brain/CNS tissue ("Cytomax" A-5), sold as oral capsules in the Russian peptide-bioregulator tradition. It is a proprietary extract, distinct from its studied relatives: the registered cerebral-cortex polypeptide drug Cortexin and the synthetic brain tetrapeptide Cortagen.

An oral capsule, commonly 20 mg, taken as a course: typically 1-2 capsules daily for 10-30 days, repeated 2-3 times per year. No reconstitution, no injection. This is the conventional bioregulator schedule, not a validated therapeutic dose.

The real neuroprotection data belong to the registered preparation Cortexin (cattle cerebral-cortex polypeptides, 1-10 kDa, dosed 20 mg IM daily in 10-day courses) and the synthetic analog Cortagen. Cerluten itself is a proprietary oral extract with Russian-language, largely open-label human data. Not a drug, not FDA-approved, and its claims are unconfirmed by Western trials.

Quickstart Highlights

Cerluten (product code A-5) is a natural peptide complex extracted from the brain / central nervous system tissue of young animals, sold in oral capsules as the CNS member of the Russian “Cytomax” peptide bioregulators[1][4]. It is marketed for “brain and neuron support,” cognition and neuroprotection.

The honest framing is the same as for the whole family: the real neuroprotection data belong to Cerluten’s defined relatives — the registered cerebral-cortex polypeptide preparation Cortexin and the synthetic brain analog Cortagen — not to this specific extract[2][3]. Cerluten itself is a natural extract of proprietary composition with Russian-language, largely uncontrolled human data, and it is not a drug and not FDA-approved. This page is an educational reference, not medical advice, and self-treating a neurological condition with a grey-market extract is not a substitute for a neurologist.

Supplies Needed

Cerluten is an oral capsule, so there is no reconstitution kit and no injection equipment. What matters is a genuine, well-stored product from a source you trust; as a natural brain-tissue extract, identity and storage matter more than for a defined synthetic peptide.

Protocol Overview

Cerluten is the brain/CNS member of the Cytomax family of natural peptide extracts, sold as an oral bioregulator for cognition and neuroprotection in the Khavinson tradition[1][4]. Its rationale is the peptide theory of ageing: short, tissue-specific peptides are proposed to help normalise function in the organ they derive from — here, the brain.

The overview’s honest core is the gap between the family’s best science and this product. The neuroprotection data belong to Cortexin, a registered preparation of cattle cerebral-cortex polypeptides (1–10 kDa) with reported clinical efficacy in cerebrovascular disease and stroke, and to the synthetic analog Cortagen[2][3]. Cerluten is the natural oral extract, of proprietary composition, with Russian-language and largely uncontrolled human data — a parapharmaceutical, not an approved drug.

Dosing Protocol

Because Cerluten is an oral capsule, the “protocol” below is a course schedule, not a reconstitution ladder. These figures are the conventional bioregulator regimen, not a clinically validated dose for this extract (the studied Cortexin regimen is shown for contrast).

Capsule

20 mg brain/CNS peptide complex

Oral; no reconstitution

Course

1–2 caps daily × 10–30 days

Often before a meal

Repeat

2–3 courses per year

Conventional “pulse” pattern

Studied drug for contrast[3]

Cortexin 20 mg IM daily × 10 d

Different product/route

Why Cerluten draws research interest

These are the directions researchers and the peptide community most often explore Cerluten for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

The neuroprotection data are Cortexin’s, not Cerluten’s

The clinical neuroprotection literature people point to is for Cortexin — a registered injectable preparation of cattle cerebral-cortex polypeptides, studied in stroke and cerebrovascular disease at 20 mg intramuscularly in 10-day courses. Cerluten is the oral natural extract sold as a Cytomax capsule. It is a relative of Cortexin, not the drug that was actually studied, and the honest reading keeps those two apart.

A brain-tissue extract has no fixed formula

Cerluten is purified from animal brain/CNS tissue, so its contents are set by manufacturing rather than a defined structure. Batch consistency depends on the maker, a grey-market copy has no guarantee of identity, and being animal-derived it carries the general considerations of tissue-sourced products. This is a different category from a synthetic peptide of known sequence.

The human evidence is Russian-only and mostly open-label

Even for Cortexin, the supportive clinical literature is overwhelmingly Russian-language and frequently unmasked; for the natural extract Cerluten there is essentially no independent Western controlled evidence at all. It is sold as a parapharmaceutical, not an approved medicine, and its cognitive/neuroprotective claims should be read as an unconfirmed hypothesis rather than established fact.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

An oral capsule, commonly 20 mg of brain/CNS peptide complex. No vial, no reconstitution, no needle.

Typically 1–2 capsules daily for a 10–30 day course, repeated 2–3 times per year[4]. A conventional bioregulator schedule, not an FDA-cleared regimen.

The registered cortex preparation Cortexin (cattle cerebral-cortex polypeptides) has the neuroprotection data[2][3]; Cerluten is the natural extract, not that studied drug.

Bioregulator — Russian-only, largely uncontrolled. Cortexin/Cortagen data are real but Russian and mostly open-label; the extract’s own claims are unconfirmed by Western trials. Not FDA-approved.

Oral Dosing Guide

Cerluten is dosed like a supplement course, not a titrated drug: oral capsules daily for a set number of days, then a break, repeated a few times a year[4]. What follows is that convention, framed honestly against the fact that the controlled neuroprotection data are for Cortexin, not this extract[2][3].

Standard / Gradual Approach

The conventional bioregulator regimen is 1–2 capsules (commonly 20 mg each) once daily for a 10–30 day course, usually before a meal, with courses repeated 2–3 times per year[4]. This short-course, long-gap “pulse” pattern is shared across the Cytomax line.

It is worth contrasting this with how the studied brain-cortex preparation is used: Cortexin is given intramuscularly at 20 mg daily (10 mg morning + 10 mg evening) for 10 days, often with a repeat course, in the clinical stroke literature[3]. That is a different product, route and setting from an oral Cytomax capsule — a reminder that the neuroprotection evidence does not directly transfer to Cerluten.

Because there is no validated dose-response for the extract, more is not better, and stacking several organ bioregulators has no controlled support. The capsule amount is a manufacturing convention; anyone following it is copying a bioregulator schedule for a proprietary natural extract whose own effects have not been demonstrated in controlled Western trials.

Storage Instructions

Keep Cerluten capsules in a cool, dry place, sealed and out of light, per the supplier’s guidance. As a natural peptide extract it is more sensitive to poor storage than a simple synthetic compound.

Because it is an animal-tissue extract, source and handling matter: a genuine, properly stored product from a reputable maker is very different from an unverified grey-market copy with no guarantee of identity or purity.

Important Notes

These are the points most often lost when Cerluten is marketed internationally as a “brain peptide.”

▪The neuroprotection data belong to Cortexin: the stroke and cerebrovascular efficacy literature is for the registered Cortexin preparation (and the analog Cortagen), not Cerluten[2][3]. Treating that as the extract’s own evidence is the core error to avoid.

▪It is a natural extract, not a defined molecule: the capsule contains a proprietary brain/CNS peptide complex, so composition is set by manufacturing and grey-market copies have no guarantee of identity[4].

▪The human evidence is Russian-only and mostly open-label: supportive studies are overwhelmingly Russian-language and frequently unmasked[3]; independent Western controlled trials of Cerluten do not exist.

▪It is a parapharmaceutical, not a drug: Cerluten is not FDA-approved and is sold as a supplement. It should not replace medical care for a neurological condition.

▪Animal-derived: being purified from animal brain tissue, it carries the general considerations of tissue-sourced biologicals; quality and sourcing matter accordingly.

How This Works

The proposed mechanism is the peptide theory of ageing applied to the brain: short, tissue-specific peptides from nervous tissue are proposed to act as organotropic regulators, supporting neuronal metabolism and resilience even at low concentrations[1].

The concrete data come from the registered Cortexin preparation, a complex of low-molecular-weight (1–10 kDa) cattle cerebral-cortex polypeptides described as organotropic to the cortex. In the cerebrovascular literature it is proposed to blunt the ischemic cascade — glutamate excitotoxicity, oxidative stress and neuroinflammation — and its clinical use in stroke has been reported in numerous (Russian, mostly open-label) studies[2][3]. The synthetic brain analog Cortagen shares this proposed cortex-directed activity.

The honest limit is that this is Cortexin biology, in Russian open-label settings, and it does not establish that the oral natural extract Cerluten produces the same effects. The mechanism is a coherent, long-standing hypothesis with real (if unmasked) clinical reports for the registered drug — not controlled human proof for this capsule[4].

Lifestyle Factors

For brain health and cognition, the interventions with the strongest evidence are behavioural and vascular: regular aerobic exercise, managing blood pressure and cardiovascular risk, sleep, cognitive and social engagement, and treating conditions like depression or sleep apnoea. These do far more for the brain than any oral peptide extract.

The honest “daily habits” note is a redirection: proven brain-health basics carry evidence that a Russian-tradition bioregulator does not, and they avoid the unknowns of a proprietary animal-tissue extract taken for a serious neurological concern.

Potential Benefits & Side Effects

Evidence tier: bioregulator — real data for the registered analog Cortexin (Russian, mostly open-label), but none for the extract itself in controlled Western trials. The “effects” below are largely Cortexin/Cortagen findings; the “considerations” are the honest counterweight.

Reported Effects

▪Reported neuroprotection — Cortexin data: the registered cerebral-cortex preparation is reported to improve outcomes in ischemic stroke and cerebrovascular disease in Russian clinical studies[2][3].

▪Proposed anti-excitotoxic action — mechanistic: Cortexin is described as blunting glutamate excitotoxicity, oxidative stress and neuroinflammation in the ischemic cascade[2].

▪Organotropic peptide concept: low-molecular-weight cortex peptides are proposed to act tissue-specifically on neurons at low concentrations[1][3].

▪What is not established: that the oral natural extract Cerluten reproduces any of this in humans. There are no Western controlled trials of the extract, and even the Cortexin data are largely open-label[4].

Common Side Effects

▪Reported tolerability is good — from uncontrolled studies: the bioregulators and Cortexin are described as well tolerated, but open-label Russian data are poor at detecting and attributing adverse effects[3].

▪Natural-extract uncertainty: composition is proprietary and animal-derived, so the true content and purity of any product — especially a grey-market copy — are not guaranteed.

▪Neurological caution: a product aimed at the CNS should never replace evaluation of new neurological symptoms, which can signal serious, treatable disease.

▪Western safety data are absent: without controlled trials outside Russia, the international side-effect profile of Cerluten is not independently characterised.

Oral Administration

Cerluten is taken by mouth as a capsule — there is no mixing, no needle and no injection technique. The steps below keep an oral bioregulator course simple and consistent; they are educational, not medical instructions.

Before You Dose

▪Confirm the product and course: check that you have a genuine brain/CNS bioregulator and know your course length (commonly 10–30 days) and daily capsule count.

▪Understand what it is: a natural brain-tissue extract sold as a parapharmaceutical, not the registered drug Cortexin — frame expectations accordingly.

▪Have water ready: capsules are usually taken 15–20 minutes before a meal with water.

How To Take

▪Swallow whole: take the capsule(s) with water, before a meal, once daily unless a specific product directs otherwise.

▪Keep to the course: take it consistently for the course length, then stop — the convention is a short course, not continuous use.

▪Do not over-stack: avoid combining many organ bioregulators; there is no controlled evidence for combinations.

After Dosing

▪Take the gap: after a course, leave the conventional multi-month interval before repeating.

▪Watch how you feel: treat any new or unusual neurological symptom as a reason to stop and seek medical assessment.

▪Store it properly: reseal and keep capsules cool, dry and out of light.

Recommended Source

For high-purity Cerluten (20 mg oral), we point researchers to Prime Lab Peptides.

Why Prime Lab Peptides?

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.

▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.

▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.

▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.

▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

References

View Source ↗

How to take Cerluten

1Confirm the capsule strength and your target dose from the schedule on this page (each capsule is a fixed strength).

2Take the required number of Cerluten capsules by mouth once daily, swallowed whole with water, with or without food.

3Keep the daily dose consistent and follow any documented gradual 4-week escalation steps.

4Store the capsules sealed at room temperature, dry and away from light — no mixing or refrigeration needed.

Cerluten — frequently asked questions

Cerluten is taken by mouth as one or more capsules once daily, swallowed whole with or without food. There is no mixing, reconstitution, or injection — it is an oral small-molecule compound, not an injectable peptide.

No. Because Cerluten is an oral capsule, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — you simply take the capsule(s) by mouth.

Each capsule is a fixed strength, so a target dose is reached by taking the matching number of capsules at that strength. The dosing table on this page lists the reference dose for each step of a documented research schedule — match your capsule strength to it rather than assuming a fixed number.

Keep the capsules in their original sealed container at controlled room temperature, dry and away from heat, light and moisture, and follow the specific storage guidance supplied with your product. No refrigeration or reconstitution is required.

The main practical difference is the route of administration: Cerluten is swallowed as a capsule, so there is no reconstitution, bacteriostatic water, or sterile injection technique involved. Its specific mechanism of action and the research behind it are described in the "How This Works" section on this page.

No. Research-grade Cerluten is supplied strictly for laboratory and research purposes and is not an approved medicine for human use — regardless of whether an approved pharmaceutical product containing this ingredient exists. Everything here is research information, not medical advice; consult a licensed healthcare professional and the approved product labeling before any use.

New protocols & dosing updates

Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.

Written by Dr. Aimen Arij, PharmD

Related Bioregulators protocols

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01P21 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. P21 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Thymogen — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Thymogen is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04GHK (Copper-Free) — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. GHK (Copper-Free) is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05IGF-1 DES — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 1 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 1 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. IGF-1 DES is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Research Models and How Lipogenesis Is Actually Measured

Understanding how AOD-9604 has been studied clarifies both what the data can support and what a real antilipogenic investigation would require. The methodology falls into three tiers, and only the first touches lipogenesis directly. Ex vivo and in vitro fat-tissue work. The foundational studies examined lipolysis and lipogenesis in adipose tissue and isolated fat cells, measuring free-fatty-acid and glycerol release, fat oxidation, and — critically — the activity of lipogenic enzymes such as acetyl-CoA carboxylase.23 Enzyme-activity assays of this kind are the appropriate tool for an antilipogenic claim, and they are the source of the strongest evidence that a C-terminal domain peptide can suppress fat synthesis. A more complete modern program would add radiolabeled- or deuterium-tracer incorporation into fatty acids to quantify DNL flux, plus expression of ACC, FASN, SREBP-1c, and ChREBP under the peptide. Rodent models. The most methodologically informative animal work is the β3-AR knockout study, a clean genetic approach that isolated the receptor’s contribution by comparing knockout and wild-type mice under identical treatment.4 Obese Zucker rats and ob/ob mice provided body-weight, fat-mass, and substrate-oxidation readouts.15 These are genetically obese metabolic models, well suited to whole-body fat-balance questions but blunt instruments for isolating lipogenesis from lipolysis, since net fat change reflects both. Human trials. The clinical methodology was appropriate for an obesity drug — randomized, double-blind, placebo-controlled designs with weight and body-composition endpoints, plus dedicated safety and pharmacokinetic studies.610 A safety and tolerability study specifically characterized the peptide in humans.6 But none of these used lipogenesis endpoints. To answer this article’s question in humans would require a purpose-built study: stable-isotope measurement of de novo lipogenesis, adipose and hepatic lipogenic-gene expression, and controlled dosing — work that has never been done for AOD-9604. The methodological bottom line is that the antilipogenic evidence is strongest exactly where it is least generalizable (isolated rodent fat-tissue enzyme assays) and absent exactly where it would matter most (human DNL flux). Until that gap is filled, any statement that AOD-9604 “reduces lipogenesis in humans” is hypothesis, not finding. Terminology used across this literature — lipogenesis, lipolysis, DNL, ACC, FASN — is defined for reference in the site’s peptide and metabolism glossary.

Source: dosagepeptide.com ↗

Limitations and the Human-Evidence Gap

Every honest account of NAD+ and Parkinson’s disease converges on the same conclusion: the human evidence gap is wide, and the most important results are not yet in. It is worth cataloguing the specific limitations, because they are what separate a promising research program from a proven therapy, and because they are exactly the details that hype tends to omit. The first limitation is trial size and duration. The two completed randomized trials in Parkinson’s disease enrolled 30 and 20 participants and lasted 30 days and 4 weeks respectively.1,2 These are appropriate designs for their stated purposes, safety and target engagement, but they are structurally incapable of demonstrating disease modification, which manifests as a gradual divergence of progression curves over a year or more. Any clinical improvement seen in such short trials is more likely to reflect symptomatic effects, measurement variability, or confounding than a change in the underlying neurodegenerative process. The NR-SAFE authors’ own caution about levodopa-timing confounding their UPDRS signal is a model of the appropriate humility.2 The second limitation is the responder problem. NADPARK showed that oral NR raises brain NAD+ in some participants but not others, and that clinical and metabolic signals clustered in the responder subgroup.1 This heterogeneity is scientifically important but clinically double-edged: it means that even if NAD+ elevation helps, an intention-to-treat analysis that includes non-responders may dilute the effect below detectability, while a responder-only analysis risks the statistical pitfalls of post-hoc subgrouping. Sorting out who responds, why, and how to identify them in advance is unfinished work. The third limitation is the model-to-human translation gap already discussed. The mechanistic and preclinical case is strong, but Parkinson’s disease has an unusually long history of interventions that protected neurons in animals and then failed in rigorous human trials, from antioxidants to anti-apoptotic agents to other mitochondrial strategies. NAD+ boosting could be different, but the base rate argues for caution until the phase III data are published.1,5 The fourth limitation concerns the epidemiology: the cross-sectional NHANES analysis linking higher dietary niacin intake to lower Parkinson’s prevalence is consistent with the hypothesis but cannot establish causation, and the larger EPIC-based cohort study examined niacin and tryptophan intake against incident Parkinson’s disease without providing the kind of confirmed protective association that would strengthen the causal case.10,11 Observational designs of this type are in any event particularly vulnerable to reverse causation, because prodromal Parkinson’s disease alters diet, smell, appetite, and gastrointestinal function years before diagnosis. The fifth limitation is conceptual: “NAD+ deficiency” is not a single, cleanly measured, universally agreed entity in Parkinson’s disease. Different studies measure NAD+ in different tissues (brain, cerebrospinal fluid, blood, skeletal muscle) using different techniques, and these compartments do not move in lockstep. The finding of lower NAD+ or lower NAD+-synthesizing enzymes in some Parkinson’s tissues is real and reproducible in places, but whether it is a primary driver of neurodegeneration, a downstream consequence of mitochondrial failure, or both at once is not resolved.4,6 A therapy premised on correcting a deficiency needs a clear picture of what deficiency it is correcting and where. Until the NOPARK results and comparable trials are published and, ideally, independently replicated, the responsible bottom line is that NAD+ precursors remain an unproven, investigational approach in Parkinson’s disease, however biologically attractive the rationale.3

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗
Dosage reference

Gonadorelin (2mg Vial) Dosage Protocol

Synthetic GnRH that stimulates LH/FSH release — research/educational dosing reference.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →